Connection
Myron Levin to Cost-Benefit Analysis
This is a "connection" page, showing publications Myron Levin has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.141 |
|
|
|
-
Brisson M, Pellissier JM, Levin MJ. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis. 2007 Dec 01; 45(11):1527-9.
Score: 0.060
-
Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007 Nov 28; 25(49):8326-37.
Score: 0.060
-
Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M. Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother. 2013 May; 9(5):1177-84.
Score: 0.021